ad

ACC Q1 Results FY26: Q1 PAT Rise 4.36% to ₹375.38 crore; Revenue Surged 17.08% YoY

Posted by : sachet | Fri Jul 25 2025

ACC Q1 Results FY26: Q1 PAT Rise 4.36% to ₹375.38 crore; Revenue Surged 17.08% YoY

Acc Q1 Results FY26: ACC posted its Q1 results on 23rd July 2025. The company posted robust numbers with Q1 PAT standing at ₹ 375.38 crores against revenue of ₹ 6087.23 crores. During Q1 FY26, the profit increase of the company was recorded at 4.36% YoY, and revenue increased for the same period was 17.08%. 

ACC Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

ParticularsQuarter Ended
30-06-202530-06-2024
Revenue from Operations₹6,087.23₹5,199.09
Profit Before Tax (PBT)₹846.36₹750.8
Profit After Tax (PAT)₹375.38₹359.7

(Figures in crores)

ACC Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

ParticularsQuarter Ended
30-06-202530-06-2024
Revenue from Operations₹6,065.83₹5,199.76
Profit Before Tax (PBT)₹841.81₹747.06
Profit After Tax (PAT)₹384.5₹366.23

(Figures in crores)

ACC Results FY26 Highlights – (Q1 vs FY25)

  • ACC clocked Q1 FY26 consolidated revenue of ₹6,087.23 crores vs ₹5,199.09 crores. 
  • On the profit front, ACC earned a consolidated PAT of ₹375.38 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹359.7 crores. 
  • Consolidated PAT rose for the first quarter of FY26, was 4.36% YoY, and revenue rose 17.08% YoY. 
  • As per the standalone figures, the quarterly PAT of ACC has increased by 4.99% and revenue has increased by 16.66% YoY.

ACC Share Price Performance

On the opening bell of 24th July 2025, the shares of ACC opened at ₹1950.00 per share. However, the initial gains are wiped out as of now, and ACC shares are trading at ₹1890.00 per share, lower than their opening price. 

Considering the long-term performance, ACC shares have yielded close to -27.84% returns in the past 1 year, and 5-year returns stand at 40.65%. Over the maximum timeframe, the  ACC share provided 2,055.57% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in ACC shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Coforge Q1 Results FY26: Q1 PAT Jumps 138.29% to ₹317.40 crore; Revenue Surged 56.49% YoY

Bajaj Housing Finance Q1 Results FY26: Q1 PAT Jumps 20.86% to ₹583.30 crore; Revenue Surged 18.43% YoY

Dr Reddy’s Laboratories Q1 Results FY26: Q1 PAT Jumps 1.85% to ₹1,418.10 crore; Revenue Surged 11.38% YoY

Persistent Systems Q1 Results FY26: Q1 PAT Jumps 38.68% to ₹424.94 crore; Revenue Surged 21.79% YoY

Oracle Financial Services Q1 Results FY26: Q1 PAT Jumps 4.09% to ₹641.90 crore; Revenue Surged 6.36% YoY

Repono  IPO GMP & Review: Apply or Avoid?

PCBL Chemical Q1 Results FY26: Q1 PAT Slips 20.13% to ₹94.05 crore; Revenue Surged 1.38% YoY

Nestle India Q1 Results FY26: Q1 PAT Slips 13.40% to ₹646.59 crore; Revenue Surged 5.86% YoY

Tata Consumer Products Q1 Results FY26: Q1 PAT Rise 15.10% to ₹334.15 crore; Revenue Surged 9.81% YoY

Canara Bank Q1 Results FY26: Q1 PAT Fall 21.45 to ₹3,194.95 crore; Revenue Surged 12.11% YoY

Bikaji Foods Q1 Results FY26: Q1 PAT Jumps 2.80% to ₹59.90 crore; Revenue Surged 14.18% YoY

Brigade Hotel Ventures IPO GMP: Day 1 IPO Live Updates

Force Motors Q1 Results FY26: Q1 PAT Jumps 52.40% to ₹176.33 crore; Revenue Surged 21.88% YoY

Aditya Birla Real Estate Q1 Results FY26: Q1 PAT Drops 427.38% to -₹25.47 crore; Revenue Plunged 58.80% YoY

SRF Q1 Results FY26: Q1 PAT Jumps 71.41% to ₹432.32 crore; Revenue Surged 10.23% YoY

Infosys Q1 Results FY26: Q1 PAT Jumps 8.68% to ₹6,921.00 crore; Revenue Surged 7.54% YoY

Shanti Gold IPO GMP & Review: Apply or Avoid?

UBL Q1 Results FY26: Q1 PAT Jumps 5.95% to ₹183.87 crore; Revenue plunged 7.41% YoY

Best Defence Penny Stocks For Higher Growth in 2025

Patel Chem Specialities IPO GMP & Review: Apply or Avoid?